Pfizer Inc. $PFE is Pacer Advisors Inc.’s 10th Largest Position

Pacer Advisors Inc. reduced its holdings in shares of Pfizer Inc. (NYSE:PFE) by 11.5% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 17,574,851 shares of the biopharmaceutical company’s stock after selling 2,284,449 shares during the quarter. Pfizer makes up 1.1% of Pacer Advisors Inc.’s investment portfolio, making the stock its 10th biggest holding. Pacer Advisors Inc. owned about 0.31% of Pfizer worth $447,807,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in PFE. Fiduciary Alliance LLC boosted its position in shares of Pfizer by 46.4% in the 3rd quarter. Fiduciary Alliance LLC now owns 145,263 shares of the biopharmaceutical company’s stock valued at $3,701,000 after purchasing an additional 46,043 shares during the period. Westbourne Investments Inc. acquired a new position in Pfizer during the first quarter worth approximately $2,411,000. Bourne Lent Asset Management Inc. lifted its stake in Pfizer by 90.8% in the second quarter. Bourne Lent Asset Management Inc. now owns 38,255 shares of the biopharmaceutical company’s stock valued at $927,000 after buying an additional 18,200 shares during the last quarter. Ossiam boosted its holdings in shares of Pfizer by 71.2% in the second quarter. Ossiam now owns 5,650,573 shares of the biopharmaceutical company’s stock valued at $136,970,000 after acquiring an additional 2,349,058 shares during the period. Finally, Generali Investments CEE investicni spolecnost a.s. grew its position in shares of Pfizer by 76.4% during the third quarter. Generali Investments CEE investicni spolecnost a.s. now owns 109,269 shares of the biopharmaceutical company’s stock worth $2,784,000 after acquiring an additional 47,319 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. Citigroup started coverage on shares of Pfizer in a research note on Tuesday, December 2nd. They set a “neutral” rating and a $26.00 price target for the company. Morgan Stanley reduced their target price on shares of Pfizer from $32.00 to $28.00 and set an “equal weight” rating for the company in a report on Friday, December 12th. Wolfe Research set a $24.00 price target on Pfizer and gave the stock an “underperform” rating in a report on Wednesday, December 17th. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $26.00 price objective on shares of Pfizer in a research note on Wednesday, November 5th. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a research note on Wednesday, October 8th. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $28.06.

Pfizer Trading Up 0.7%

Shares of Pfizer stock opened at $25.05 on Friday. The firm has a market cap of $142.40 billion, a price-to-earnings ratio of 14.56 and a beta of 0.46. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $27.69. The company’s 50-day simple moving average is $25.15 and its 200-day simple moving average is $24.88. The company has a quick ratio of 0.97, a current ratio of 1.28 and a debt-to-equity ratio of 0.62.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share for the quarter, beating analysts’ consensus estimates of $0.79 by $0.08. Pfizer had a return on equity of 20.17% and a net margin of 15.65%.The company had revenue of $16.65 billion for the quarter, compared to analyst estimates of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. As a group, equities research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, January 23rd will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 6.9%. The ex-dividend date of this dividend is Friday, January 23rd. Pfizer’s dividend payout ratio is currently 100.00%.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.